Shielding heart tissue bystanders after attack, researchers discover compound


Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy heart muscle tissue.

“Cardiologists say that when a heart attack occurs, time is muscle,” said Robert Gourdie, director of the Fralin Biomedical Research Institute at VTC Center for Heart and Reparative Medicine Research.

heart attack

Robert Gourdie, a professor at the Fralin Biomedical Research Institute at VTC, is working on a way to limit the damage of hypoxic ischemic injury, allowing the nearby heart muscle cells to remain intact.

Without oxygen supplied by blood flow, heart cells die — fast. But while a heart attack may only reduce blood and oxygen to an isolated section of heart cells — causing what’s called hypoxic ischemic injury — those dying cells send signals to their neighbors.

“The problem is that the area of dying tissue is not quarantined. Damaged heart cells start to send out signals to otherwise healthy cells, and the injury becomes much bigger,” said Gourdie, who is also the Commonwealth Research Commercialization Fund Eminent Scholar in Heart Regenerative Medicine Research and a professor in the Department of Biomedical Engineering and Mechanics in the Virginia Tech College of Engineering.

Scientists sometimes call this spread of injury signals to nearby healthy tissues a “bystander effect.”

But what if there were a way to keep the injury localized to the group of cells that are directly affected by the hypoxic ischemic injury, while allowing the nearby heart muscle cells to remain intact?

A study published Aug. 19 in the Journal of the American Heart Association reveals that a new molecule developed by a team of researchers led by Gourdie could help preserve heart tissue during — and even after — a heart attack.

Nearly a decade ago Gourdie, in collaboration with a postdoctoral fellow in his lab, Gautam Ghatnekar, stumbled across a promising discovery. Gourdie’s team discovered a compound that targets the activity of channels in cell membranes responsible for controlling key aspects of the bystander effect.

But the compound, called alphaCT1, also had other unexpected and beneficial effects, particularly in relation to skin wound healing.

“We found that it helped reduce inflammation, helped heal chronic wounds such as diabetic foot ulcers,” said Gourdie.

Recognizing the compound’s potential, Ghatnekar and Gourdie founded a company, FirstString Research Inc., to commercialize alphaCT1, which is now in phase III clinical trials for treating wounds.

Meanwhile, Gourdie has been trying to understand how the drug works on a molecular level, which led to the study just published in the Journal of the American Heart Association.

“This paper asks the question: how does this peptide drug actually work?” said Gourdie.

The group designed molecules with slight chemical differences from the parent molecule, which led to an unexpected discovery. One of the alphaCT1 variants — called alphaCT11 — showed more potency than the parent molecule.

“AlphaCT11 seems to be even more effective than the original peptide in protecting hearts from ischemic injury similar to those occurring during a heart attack,” said Gourdie.

The study reveals that alphaCT11 gives a robust injury-reducing effect, even when given 20 minutes after the loss of blood flow that causes ischemic injury. When put to the same test, the parent peptide did not appear to provide a heart-protective effect when administered after ischemic injury.

“AlphaCT11 could provide the basis for a new way to treat heart attacks and prevent the spread of damage that occurs immediately after a heart attack,” said Gourdie.

The researchers perfused isolated laboratory mouse hearts, keeping the organ alive and beating for a number of hours. Ongoing studies, through collaboration with Virginia Commonwealth University’s Antonio Abbate and Stefano Toldo, will examine how alphaCT11 performs in live mice.

Gourdie is also developing new methods for delivering alphaCT11 using naturally-derived tiny lipid droplets called exosomes. These newer experiments could provide a stepping stone toward clinical trials in patients who have suffered a heart attack.

The lead co-authors, Jingbo Jiang, a pediatric cardiologist at Shenzhen Children’s Hospital in China who did her doctoral work at Virginia Tech, and Daniel Hoagland, a postdoctoral research associate, both worked in Gourdie’s lab on the study.

Other research contributors included Joseph Palatinus, a cardiology fellow at Cedars-Sinai who did his doctoral research in Gourdie’s lab; Jane Jourdan, lab manager at the Center for Heart and Reparative Medicine Research; Geert Bultynck and Jegan Iyyathurai, who work at KU Leuven; Zhiwei Zhang, of the Guangdong Cardiovascular Institute; Zhen Wang and Kevin Shey, who work at Vanderbilt University; Ryan King, a translational biology, medicine, and health graduate student at Virginia Tech; Steven Poelzing, an associate professor at the Fralin Biomedical Research Institute; and Huamei He and Francis McGowan, who work at the Children’s Hospital of Philadelphia.



uva basketball team of destiny

Team of Destiny: Inside UVA Basketball's improbable run

Team of Destiny: Inside Virginia Basketball’s Run to the 2019 National Championship, by Jerry Ratcliffe and Chris Graham, is available for $25.

The book, with additional reporting by Zach Pereles, Scott Ratcliffe and Scott German, will take you from the aftermath of the stunning first-round loss to UMBC in 2018, and how coach Tony Bennett and his team used that loss as the source of strength, through to the ACC regular-season championship, the run to the Final Four, and the thrilling overtime win over Texas Tech to win the 2019 national title, the first in school history.

Subscribe

Augusta Free Press content is available for free, as it has been since 2002, save for a disastrous one-month experiment at putting some content behind a pay wall back in 2009. (We won’t ever try that again. Almost killed us!) That said, it’s free to read, but it still costs us money to produce. The site is updated several times a day, every day, 365 days a year, 366 days on the leap year. (Stuff still happens on Christmas Day, is what we’re saying there.) AFP does well in drawing advertisers, but who couldn’t use an additional source of revenue? From time to time, readers ask us how they can support us, and we usually say, keep reading. Now we’re saying, you can drop us a few bucks, if you’re so inclined.

 


augusta free press
augusta free press
augusta free press news